Navigation Links
Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

SAN FRANCISCO, Oct. 31 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, at 11:15 a.m. Eastern Time at the New York Palace Hotel.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon(TM) for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

The Company reported results from its Phase 2 efficacy study of Dimebon in Alzheimer's disease in June 2007, showing that Dimebon improved the clinical course of patients by demonstrating meaningful improvement over placebo in each of the five disease aspects most important to patients, caregivers and physicians -- memory, thinking, activities of daily living, behavior and overall function. Significant gains in these disease aspects were evident as early as the twelfth week of treatment. After six months of treatment, patients were significantly better off than they were at the start of therapy on all key aspects of the disease. Dimebon's overall benefit compared to placebo continued to increase over time and was greater at 12 months that at six months.

A live audio webcast of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone- refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... Clinical Supplies Management ... acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). TCS ... drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across Europe. ...
(Date:12/6/2016)... 2016  SRI International has been awarded a ... National Institutes of Health,s National Institute of Allergy ... (NIAID-DAIDS) to support the manufacturing and characterization of ... Under the seven-year contract, SRI will provide a ... candidate HIV-prevention products that emerge from investigator-initiated studies ...
(Date:12/5/2016)... Bermuda , Dec. 5, 2016 Axovant ... clinical-stage biopharmaceutical company focused on the treatment of dementia, ... intepirdine for the treatment of Alzheimer,s disease will be ... (CTAD) Meeting on Friday, December 9, 2016 in ... will show results of both simple and complex measures ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of AxioMed’s ... disc production, company President, Jake Lubinski will be traveling to Germany on December ... in Cologne and Karlsruhe to discuss the benefits of a viscoelastic total disc ...
Breaking Biology Technology:
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... LONDON , Nov. 17, 2016 Global Market ... and Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market ... Geographical analysis for Private Biobanks shows the highest Compounded Annual ... Asia-Pacific region during the analysis period 2014-2020. ... a CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):